ANRO
Alto Neuroscience Inc (ANRO)
Healthcare • NYSE • $21.94-3.01%
- Symbol
- ANRO
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $21.94
- Daily Change
- -3.01%
- Market Cap
- $860.97M
- Trailing P/E
- N/A
- Forward P/E
- -6.68
- 52W High
- $37.48
- 52W Low
- $6.72
- Analyst Target
- $38.38
- Dividend Yield
- 0.00%
- Beta
- 1.34
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of a…
Company websiteResearch ANRO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.